S100A1 |
Aldolase C |
GO |
|
|
Stimulation of aldolase C activity |
[60] |
|
Annexin A5 |
F, CC |
|
|
|
[73] |
|
Annexin A6 |
CL, CI, F, CC |
|
<1000 |
Regulation of calcium flux and IF assembly |
[72,73,116] |
|
CacyBP/SIP1 |
GO, AC, F, CI |
|
|
Regulation of CacyBP/SIP |
[79] |
|
Caldesmon |
E, F, CC |
|
170 |
Decrease in inhibition of actomyosin by caldesmon |
[55] |
|
CapZ (TRTK-12) |
GO, M, CC, F, CS, O |
|
5550 |
Modulation of actin organization |
[83,117–119] |
|
Desmin |
F, O |
|
|
Inhibition of desmin intermediate filament assembly |
[120] |
|
F-actin |
CL, CS |
|
|
Regulation of actin filament polymerization |
[18] |
|
GFAP |
F, CC, CS |
|
500 |
Inhibition of GFAP assembly |
[88,121] |
|
Microtubules/tubulin |
F, CC, O |
|
6000 |
Regulation of microtubule dynamics |
[122,123] |
|
MyOD |
AC, CC, E, F, CI |
|
2 |
Inhibition of MyoD phosphorylation and DNA binding |
[124,125] |
|
NDR |
O |
|
|
Activation of NDR kinase activity |
[57] |
|
p53 |
F, CS |
|
|
Disruption of tubulin–S100A1 complex formation |
[117] |
|
Phosphoglucomutase |
GO, AC, O |
|
|
Inhibition of phosphoglucomutase activity |
[61] |
|
RAGE |
O |
|
|
Promotion of cell survival |
[68] |
|
Ryanodine receptor |
CI, OB, AC, O |
|
214 |
Regulation of ryanodine and cardiac contractility |
[70,71] |
|
SERCA2a and PLB |
AC, CI, CL, CE |
|
|
Regulation of EC-coupling in the heart |
[126] |
|
Synapsin I |
CL, C, AC, OB |
|
245 |
Regulation of catalytic activity of synapsins |
[127,128] |
|
Titin (PEVK domain) |
GO, OB, O |
|
|
Inhibition of the actin– or nebulin–PEVK interaction |
[129,130] |
|
Twitchin kinase |
OB, O |
|
|
Activation of twitchin kinase |
[131,132] |
S100A2 |
ΔNp63 |
O |
|
|
Downstream mediation of ΔNp63 |
[133] |
|
p53 |
CL, CI, AC, O |
|
|
Activation of p53 transcriptional activity |
[53] |
|
Tropomyosin |
CC, CI, CL, AC, O |
|
|
Modulation of the actin cytoskeleton organization |
[134] |
S100A4 |
CCN3 |
Y2H, AC |
|
|
Modulation of S100A4 affinity to calcium and function |
[50,135] |
|
F-actin |
CS |
|
34000 |
|
[85,136] |
|
MetAP2 |
AC, CL, CI, Y2H |
|
|
Regulation of MetAP2 |
[51] |
|
Myosin heavy chain II-A |
AC, M, CI, FT, GO, CS, CL, C, OB, O |
|
220–600 |
Regulation of cytoskeletal dynamics |
[77,77a,80,85,92–96] |
|
Myosin heavy chain II-B |
CS, O |
|
23100 |
|
[85,94,138] |
|
Tropomyosin isoform2 |
AC, CL |
|
|
Regulation of tropomyosin–actin association |
[86] |
|
p37 |
F, AC |
|
|
Increase affinity of S100A4 to calcium |
[139] |
|
p53 |
OB, CI, CE, AC, F, O |
|
9–14 |
Enhancement of p53-dependent apoptosis in tumours |
[75–77] |
|
Sept2, Sept6 and Sept7 |
AC |
|
|
|
[140] |
S100A6 |
Annexin A11 |
AC, GO, CC, CI, CL, M, O |
|
1610 |
Regulation of annexin A11 function |
[141–146] |
|
Annexin A2 |
AC, GO |
|
Very weak |
|
[74,89,145] |
|
Annexin A5 |
GO |
|
Very weak |
|
[145] |
|
Annexin A6 |
AC, O |
|
|
|
[74] |
|
CacyBP |
F, M, NMR, AC, GO, O |
|
960 |
|
[141,147] |
|
CacyBP/SIP |
AC, CI, O |
|
|
Regulation of CacyBP/SIP ubiquitinylation complex |
[79] |
|
Caldesmon |
F |
|
|
|
[148] |
|
Fetuin (biotinylated) |
O |
|
|
|
[149] |
|
GADPH |
AC, GO, F, CS, O |
|
100 |
|
[74,89,150] |
|
Lysozyme |
GO |
|
|
|
[151] |
|
Tropomyosin |
F, O |
|
0.3–1 |
Regulation of smooth muscle contraction |
[152] |
|
Sgt1 |
AC, CC, CI |
|
|
Regulation of protein ubiquitination via Stg1 |
[59] |
S100A8/S100A9 |
Cytochrome b558
|
O |
|
|
Activation of cytochrome b558
|
[153] |
|
Glycosaminoglycans |
O |
|
6 |
Localization of MRPs to endothelium |
[154] |
|
S100A8/S100A9 (tetramer) |
MS, O |
|
|
Increasing affinity for calcium |
[155,156] |
S100A11 |
Actin |
CS |
|
1000 |
Regulation of actin activated myosin ATPase |
[157] |
|
Annexin A1 |
X-Ray, F, M, CL, AC, CI, CS, O |
|
15000 |
Targeting and membrane cross linking |
[46,66,158,159] |
S100A12 |
Annexin A5 |
AC, OB |
|
621 |
|
[160] |
|
CacyBP/SIP |
AC, O |
|
|
Degradation of α/β-catenin |
[79] |
|
Paramyosin |
E, O |
|
|
Development of keratitis |
[161] |
|
RAGE |
CD, E, O |
|
|
Inflammatory processes |
[67,162] |
|
S100A12 (hexamer) |
X-Ray |
|
|
Receptor signaling |
[163] |
S100B |
AHNAK |
AC, CI, OB |
|
50 |
Regulation of calcium homoeostasis |
[164] |
|
Aldolase C |
GO |
|
|
Stimulation of aldolase C activity |
[60] |
|
Annexin A6 |
CL, CI, F, CC |
|
<1000 |
Regulation of calcium flux and IF assembly |
[72,73,116] |
|
CacyBP/SIP |
GO, AC, CI, F |
|
|
Regulation of ubiquitination |
[55] |
|
Caldesmon |
E, F, CC |
|
500 |
Decrease in inhibition of actomyosin by caldesmon |
[79] |
|
CapZ (TRTK-12) |
NMR, F, AC, CC, O |
|
150–1000 |
Regulation of actin filament extension |
[43,45,65,84,165] |
|
FtsZ |
CL, AC |
|
|
|
[64] |
|
GFAP |
O |
|
|
Assembly of intermediate filaments |
[63] |
|
Guanylate cyclase |
O |
|
2000 |
Activation of guanylate cyclase |
[166] |
|
Intermediate filaments |
CC, CL, O |
|
|
Regulation of IF assembly and disassembly |
[167] |
|
IQGAP1 |
CL, CI, AC |
|
|
Membrane rearrangement |
[168] |
|
MAG |
AC, CC, O |
|
7000 |
Regulation of glial cell cytoskeleton |
[169] |
|
Microtubules |
Cl, O |
|
|
Regulation of microtubule dynamics |
[62] |
|
NDR |
NMR, AC, O |
|
500 |
Modulation of NDR kinase activity |
[42,57] |
|
Neuromodulin |
CC |
|
|
Inhibition of neuromodulin phosphorylation by PKC |
[170] |
|
p53 |
NMR, AC, F, OB, O |
|
24–23500 |
Inhibition of p53 function |
[47,78,110,171–173] |
|
Phosphoglucomutase |
GO, AC, M, O |
|
|
Stimulation of phosphoglucomutase activity |
[61,174] |
|
RAGE |
O |
|
|
Promotion of cell survival |
[68] |
|
Tau |
AC, CC |
|
100–1000 |
Inhibition of tau phosphorylation by protein kinase II |
[56,175] |
S100P |
CacyBP |
O |
|
|
|
[79] |
|
Dormant ezrin |
AC, CL |
|
|
Regulation of ezrin ability to bind actin |
[176] |
|
Melittin |
F, CD, O |
|
5000 |
|
[97] |
|
RAGE |
CI |
|
|
Stimulation of cell proliferation and survival via RAGE |
[69,177] |
|
S100PBPR |
AC, CI, O |
|
|
Involvement in early pancreatic cancer |
[178] |
|
Sgt1 |
AC |
|
|
|
[59] |